Adamas Announces New Employment Inducement Grant
September 11 2017 - 5:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the
compensation committee of the company’s board of directors granted
four new employees stock options to purchase an aggregate of 15,450
shares of the company’s common stock, at a per share exercise price
of $20.77, the closing trading price on September 11, 2017, and
restricted stock units to acquire 7,725 shares of the company’s
common stock. The stock option and restricted stock units vest over
four years and were granted pursuant to the Adamas Pharmaceuticals,
Inc. 2016 Inducement Plan, which was approved by the company's
board of directors in March 2016 under Rule 5653(c)(4) of the
Nasdaq Global Market for equity grants to induce new employees to
enter into employment with the company.
About Adamas Pharmaceuticals,
Inc.At Adamas, we believe in the power and the promise of
medicines derived from a deep understanding of time-dependent
biology. Our expertise lies in uncovering and mapping the
relationship between disease and drug activity. From there, we
strive to create medicines with therapeutic profiles that match the
pattern of disease to drive a more significant and durable clinical
effect. This understanding of time-dependent biological processes
informs our every innovation, targeting advancement in treatment of
chronic neurologic disorders. Our portfolio includes: GOCOVRITM
(amantadine) extended release capsules (previously ADS-5102), the
first and only FDA-approved medicine for the treatment of
dyskinesia in patients with Parkinson’s disease receiving
levodopa-based therapy, with or without concomitant dopaminergic
medications; ADS-5102 in development for the treatment of multiple
sclerosis walking impairment, and ADS-4101, a high-dose,
modified-release lacosamide in Phase 1 clinical development for the
treatment of partial onset seizures in patients with epilepsy.
Additionally, Adamas’s licensed assets are currently marketed by
Allergan under the brand names NAMENDA XR® and NAMZARIC®, and
Adamas is eligible to receive royalties on sales of these medicines
beginning in June 2018 and May 2020, respectively. For more
information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH
& Co. KGaA.
Contact:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
ir@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Sep 2023 to Sep 2024